MA53236A - Traitement des malignités des lymphocytes b - Google Patents

Traitement des malignités des lymphocytes b

Info

Publication number
MA53236A
MA53236A MA053236A MA53236A MA53236A MA 53236 A MA53236 A MA 53236A MA 053236 A MA053236 A MA 053236A MA 53236 A MA53236 A MA 53236A MA 53236 A MA53236 A MA 53236A
Authority
MA
Morocco
Prior art keywords
malignities
lymphocyte
treatment
lymphocyte malignities
Prior art date
Application number
MA053236A
Other languages
English (en)
French (fr)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MA53236A publication Critical patent/MA53236A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA053236A 2018-08-14 2019-08-13 Traitement des malignités des lymphocytes b MA53236A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US201962836511P 2019-04-19 2019-04-19

Publications (1)

Publication Number Publication Date
MA53236A true MA53236A (fr) 2021-06-23

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053236A MA53236A (fr) 2018-08-14 2019-08-13 Traitement des malignités des lymphocytes b

Country Status (14)

Country Link
US (1) US20210299134A1 (enExample)
EP (1) EP3836935A4 (enExample)
JP (1) JP2021534115A (enExample)
KR (1) KR20210043635A (enExample)
CN (1) CN112888441A (enExample)
AU (1) AU2019321432A1 (enExample)
BR (1) BR112021002760A2 (enExample)
CA (1) CA3109184A1 (enExample)
IL (1) IL280726A (enExample)
MA (1) MA53236A (enExample)
MX (1) MX2021001606A (enExample)
SG (1) SG11202101450VA (enExample)
TW (1) TW202021591A (enExample)
WO (1) WO2020036999A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
CN107501241B (zh) * 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2017035234A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11365252B2 (en) * 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Also Published As

Publication number Publication date
JP2021534115A (ja) 2021-12-09
CA3109184A1 (en) 2020-02-20
IL280726A (en) 2021-03-25
SG11202101450VA (en) 2021-03-30
TW202021591A (zh) 2020-06-16
EP3836935A1 (en) 2021-06-23
US20210299134A1 (en) 2021-09-30
EP3836935A4 (en) 2022-09-14
MX2021001606A (es) 2021-04-19
KR20210043635A (ko) 2021-04-21
BR112021002760A2 (pt) 2021-05-11
CN112888441A (zh) 2021-06-01
WO2020036999A1 (en) 2020-02-20
AU2019321432A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
EP3813647A4 (en) MULTIMODAL STIMULATION FOR TREMOR TREATMENT
EP3765960A4 (en) EVENT STREAM PROCESSING
EP3779023A4 (en) CLOTHING TREATMENT DEVICE
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3538548A4 (en) IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MA45192A (fr) Traitement d'association
EP3832007A4 (en) CLOTHING TREATMENT DEVICE
EP3448875A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3503890A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF DYSTONIA
MA47820A (fr) Traitement de la glycogénose de type iii
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
EP3749064A4 (en) PLASMA PROCESSING MACHINE
EP3740246A4 (en) INTERRUPTION OF THE LINC COMPLEX FOR THE TREATMENT OF LAMINOPATHY
EP3866777A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
EP3908292A4 (en) IMPROVED TARGETED T-CELL THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
EP3873528A4 (en) Rasopathy treatment
EP3773221A4 (en) TREATMENT OF HYDROCEPHALUS
EP3735209A4 (en) TREATMENT OF THE PROGRESSION OF MYOPOIA
EP3933099A4 (en) LAUNDRY TREATMENT DEVICE
EP3347032A4 (en) TREATMENT OF ASZITES
EP3903725A4 (en) CONNECTION STRUCTURE FOR PROCESSING
EP3881566A4 (en) AUDIO PROCESSING